Latest news with #proteomics
Yahoo
4 days ago
- Business
- Yahoo
Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON, July 25, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Proteomics: Technologies and Global Markets" was valued at $27.6 billion in 2024 and is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030. The report offers a detailed analysis of the global market for proteomic technologies, segmented by product type (instruments and software, consumables), platform (mass spectrometry, biochip), application (drug discovery and development, research, diagnostics, applied proteomics), and region (North America, Europe, Asia-Pacific, and Rest of the World). Protein structural analysis and protein-expression products are outside the scope of the report. The study discusses market trends, challenges, and emerging technologies, while also examining the competitive landscape and the market shares of leading vendors. It includes a section on ESG trends and provides company profiles that include insights into financials, product portfolios, and recent advances. This analysis serves as a valuable resource for understanding strategic opportunities and market dynamics in the evolving proteomics sector. This report is particularly relevant today due to the growing demand for innovative and personalized therapies, which is driving advances in proteomic technologies. Increased investments in R&D are accelerating the discovery of new biomarkers, which are crucial for early and accurate diagnosis of diseases. These trends underscore the importance of proteomics in shaping the future of precision medicine and improving healthcare outcomes. The factors driving the market's growth include: Increasing Investments in R&D: Governments, biotech firms, and academic institutions are increasing funding in proteomics research to drive innovation in diagnostics, drug discovery, and therapeutic development. Transition Towards Personalized Medicine: Proteomics enables the identification of protein biomarkers that support tailored treatments based on individual biological profiles, making it a cornerstone in the shift toward personalized healthcare. Aging Population and Prevalence of Chronic Diseases: As the global population ages, chronic conditions like cancer and cardiovascular diseases are becoming more common, increasing the demand for proteomics tools that aid in early detection and targeted treatment. Emerging Technologies: Advances such as high-resolution mass spectrometry, AI-driven data analysis, and single-cell proteomics are accelerating research making it more precise, and cost-effective, thereby expanding the scope and impact of proteomics. Request a sample copy of the global market for proteomic technologies report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $27.6 billion Market size forecast $57.2 billion Growth rate CAGR of 13.0% from 2025 to 2030 Segments covered Platform, Application, Product Type and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Rest of Asia-Pacific, and Rest of Europe Market drivers Increasing investments in R&D. Transition towards personalized medicine. Aging population and growing prevalence of chronic diseases. Emerging technologies. Interesting facts: Advances in Technology: The market has seen notable progress in mass spectrometry, particularly with improvements in software and automation that streamline essential processes like sample preparation. Innovation from Emerging Companies: Start-up companies such as Nautilus and SomaLogic have introduced innovative platforms that are expected to reshape the market's future. Emerging startup: Alamar Biosciences Nautilus Biotechnology Pixelgen Technologies Syncell Inc. Sengenics The report addresses the following questions: What is the projected size and growth rate of the market?- The global proteomics market was valued at $27.6 billion in 2024 and is expected to grow at a CAGR of 13% to reach $57.2 billion by the end of 2030. Which factors are driving the growth of the market?- The global market of proteomic technologies is growing due to the rising aging population and growing prevalence of chronic diseases, increasing investments in R&D and in the biotechnology sector, and rising demand for personalized medicine. Which market segments are covered in the report?- The global market for proteomic technologies is segmented based on platform, product type, application, and region. Which platform type will be dominant through 2030?- The mass spectrometry segment will be dominant through 2030. Which region has the largest market share?- North America holds the largest share of the market. Market Leaders include: AGILENT TECHNOLOGIES INC. ARRAYIT CORP. BIO-RAD LABORATORIES INC. BIO-TECHNE BRUKER CREATIVE PROTEOMICS DANAHER CORP. JEOL LTD. MERCK KGAA PROMEGA CORP. REVVITY SHIMADZU CORP. STANDARD BIOTOOLS THERMO FISHER SCIENTIFIC INC. WATERS CORP. Related reports: Single-Cell Genomics and Proteomics: Emerging Technologies and Markets: This report reviews the single-cell genomics and proteomics market, highlighting its current landscape and future potential. It examines key market drivers, challenges, and opportunities, and segments the market by product type (genomics, epigenomics, transcriptomics), application areas (oncology and immunology), end users (academic institutions and biotech companies), and regions (North America, Europe, Asia-Pacific, and the Rest of the World). It also includes profiles of major companies, covering their business segments, financials, product offerings, and recent developments. Global Multiomics Market: This report provides a detailed analysis of the global multiomics market, focusing on products, platforms, applications, end-users, and regions. It explores market trends and forecasts, along with insights into major players and geographic opportunities. The report also includes strategic tools like PESTEL and ESG analysis, competitive assessments, and recommendations to help companies plan effectively. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
Globe and Mail
21-07-2025
- Business
- Globe and Mail
Quantum-Si to Participate in the Canaccord Genuity 45th Annual Growth Conference
Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the Canaccord Genuity 45 th Annual Growth Conference taking place at the InterContinental Boston Hotel, August 12-14, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer will be taking one-on-one meetings throughout the day on Tuesday, August 12, 2025 and will participate in a fireside chat on the same day at 4:00 PM Eastern Time. A live and archived webcast of the event will be available in the 'Investors' section of the Quantum-Si website under Events & Presentations. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X.
Yahoo
15-07-2025
- Business
- Yahoo
Increasing Automation for End-to-End Proteomics Workflow & Growing Research to Identify Disease Biomarkers
The Asia-Pacific proteomics market is expected to soar from $6.95 billion in 2024 to $25.78 billion by 2034, demonstrating a robust CAGR of 14.01%. This rapid expansion is fueled by advances in next-generation sequencing and mass spectrometry technologies enabling precise protein analysis, alongside a growing emphasis on personalized healthcare, biomarker discovery, and disease profiling. Public-private collaborations and government-backed R&D initiatives are accelerating proteomics innovation, promoting precision medicine, and addressing the region's rising chronic disease prevalence and aging population. Despite challenges such as high costs and limited skilled personnel, APAC's investment in life sciences underscores proteomics as key to healthcare innovation. Asia-Pacific Proteomics Market Dublin, July 15, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Proteomics Market: Focus on Offerings, Application, and Country - Analysis and Forecast, 2024-2034" report has been added to Asia-Pacific proteomics market is projected to reach $25.78 billion by 2034 from $6.95 billion in 2024, growing at a CAGR of 14.01% during the forecast period 2024-2034. The Asia-Pacific (APAC) proteomics industry is expanding rapidly due to developments in next-generation sequencing technologies that provide high-precision protein analysis and mass spectrometry. The growing emphasis on individualised healthcare, together with increased attempts to find new biomarkers and improve disease profiling tools, is another factor contributing to this trend. New proteomic applications are being developed more quickly thanks to expanding public-private partnerships and cooperation between hospitals, biotech companies, and academic institutions, while governments around APAC are promoting research and innovation through national financing programs. Furthermore, there is an urgent need for better diagnostic instruments and early detection techniques due to the region's growing senior population and the increase in the prevalence of chronic is emerging as a key pillar in promoting precision medicine and healthcare innovation across the region as APAC keeps investing in life sciences and fortifying its clinical research IntroductionProteomics is a fast developing, high-potential market in the life sciences and biotechnology sector in Asia-Pacific (APAC). Proteomic solutions are increasingly being used in research, diagnostics, and drug development applications throughout the region, driven by developments in analytical technologies including mass spectrometry, next-generation sequencing (NGS), and bioinformatics. The need for more in-depth protein-level insights in clinical and translational research is being fuelled by rising healthcare expenditures, the incidence of chronic diseases, and the trend towards personalised in China, India, Japan, South Korea, and Singapore promote proteomics through national R&D initiatives, infrastructure development, and financial programs. Innovation in proteomics techniques and platforms is also being accelerated by public-private partnerships among biotech companies, academic institutions, and healthcare providers. Furthermore, accuracy, speed, and scalability are being improved by the increasing integration of AI and machine learning in protein data these developments, issues including exorbitant technological costs, a shortage of qualified personnel, and restricted access to cutting-edge research facilities in underdeveloped countries continue to exist. But as interest in and funding for precision healthcare continue to rise, the APAC proteomics market is expected to grow steadily and play a significant part in changing diagnostic and treatment approaches throughout the area. How can this report add value to an organization?Product/Innovation Strategy: The Asia-Pacific proteomics market has been extensively segmented based on various categories, such as offering, application, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming Strategy: The Asia-Pacific proteomics market has numerous established players with product and service portfolios. Key players in the Asia-Pacific proteomics market analyzed and profiled in the study involve established players offering proteomics products and services. APAC Proteomics Market Trends, Drivers and Challenges Trends Increasing adoption of high-throughput technologies like mass spectrometry and next-generation sequencing Rising focus on personalized medicine and precision healthcare Expansion of proteomic applications in disease diagnostics, drug development, and biomarker discovery Growth in academic-industry collaborations and public-private research partnerships Integration of AI and bioinformatics in proteomic data analysis Drivers Government support through national R&D programs and healthcare modernization initiatives Growing investment by biotech and pharmaceutical companies in proteomic research Rising prevalence of chronic diseases and aging population driving demand for early detection Increased healthcare spending and improved infrastructure across emerging APAC economies Surge in clinical trials and translational research efforts in the region Challenges High cost of proteomics instruments and data analysis platforms Limited access to advanced technologies in low- and middle-income countries Shortage of skilled professionals and bioinformatics expertise Complex data interpretation and standardization issues Regulatory and ethical concerns around patient data use and biomarker validation Key Attributes: Report Attribute Details No. of Pages 81 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $6.95 Billion Forecasted Market Value (USD) by 2034 $25.78 Billion Compound Annual Growth Rate 14.0% Regions Covered Asia Pacific Market Dynamics Trends: Current and Future Impact Assessment Increasing Automation for End-to-End Proteomics Workflow Significant Number of Collaborations among Market Players Growing Proteomics Research to Identify Disease Biomarkers Market Outlook Comparative Advantages and Disadvantages of Proteomics Over Other Omics Proteomics Techniques by Introduction with Principles and Advantages/Limitations Market Drivers Increasing Prevalence of Chronic Diseases Increasing Technological Advancements Advancements in Personalized Medicine and Drug Discovery Market Restraints Shortage of Skilled Professionals Complexity in Analyzing Data of Proteomics Research Market Opportunities Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes Regulatory Framework Japan Regulatory Requirements for Proteomics Products Intended as Medical Devices Regulatory Requirements for Clinical Proteomics Labs in Japan China Regulatory Requirements for Proteomics Products Intended as Medical Devices Asia-Pacific Proteomics Market Scenario Realistic Scenario Optimistic Scenario Pessimistic Scenario Patent Analysis Product BenchmarkingCompanies Featured Takara Bio Inc. Market Segmentation: Offering Product Service Application Drug Discovery Clinical Diagnostics Others Region Asia-Pacific China Japan India South Korea Australia Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
OraSure Launches Novel Blood Collection Device for Proteomic Research
The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research BETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ('OTI') (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed by OTI subsidiary DNA Genotek, is an evacuated blood collection tube (BCT) designed to preserve and stabilize plasma proteins in whole blood for up to seven days.* Currently available for research use only**, the collection tube with its proprietary stabilizing liquid preserves plasma proteins, facilitating storage and transport of blood samples at ambient temperature, which are limitations of general blood collection tubes. It is anticipated that the use of the product for sample collection will deliver operational and financial efficiencies to proteomic researchers and support the generation of high-quality data. "The HEMAcollect™●PROTEIN BCT represents a significant advancement in sample collection for proteomics, providing researchers with a reliable solution that preserves sample integrity and improves preanalytical workflows," said Carrie Eglinton Manner, President and CEO of OTI. "We're dedicated to enhancing the quality of insights for researchers through our innovative sample management solutions. The launch of this solution for blood proteomics applications is a clear reflection of that commitment and enables research applications in oncology, neurology, cardiology, metabolic disorders, and beyond.' The HEMAcollect™●PROTEIN BCT, powered by ProteoPrecision™ technology, minimizes hemolysis and activation of platelets, ensuring the sample accurately reflects the body's state at collection. It is compatible with a broad range of proteomic technologies including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. For more information, visit About OraSure Technologies OraSure Technologies, Inc. ('OraSure' and 'OTI') transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit About DNA Genotek DNA Genotek, a subsidiary of OraSure Technologies, Inc., develops products that optimize ease of collection and provide superior samples and proven performance for those requiring high-quality biological samples. High-quality samples that are easily collected from target populations enable our customers to focus on translating their analysis and testing into significant worldwide advancements in health and science. DNA Genotek's products are marketed worldwide and support thousands of customers as they achieve breakthroughs in genomic research, in diagnostics laboratories, in the pharmaceutical industry, in livestock and animal genomics, and in personal genomics. For more information about DNA Genotek, visit Forward Looking Statements This press release contains certain 'forward-looking statements,' including with respect to products, product candidate development and regulatory authorizations and other matters. Forward-looking statements are based on current expectations of future events and are not guarantees of future performance or results. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: uncertainty of commercial success; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; uncertainty of regulatory approvals; ability to comply with applicable regulatory requirements; uncertainty relating to patent protection and potential patent infringement claims; impact of competitors, competing products and technology changes and patents obtained by competitors; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; impact of negative economic conditions; changes in behavior and spending patterns of purchasers; trends toward healthcare cost containment; product efficacy or safety concerns resulting in product recalls or regulatory action; and changes to applicable laws and regulations. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements. * Stabilization is determined from a representative subset of plasma proteins. ** For research use only. Not for use in diagnostic procedures. Some DNA Genotek Inc. products are not available in all geographic regions. Customers must review the labels of sample collection devices and ensure compliance with their intended use. Investor Contact:Jason PlagmanVice President, Investor Relationsinvestorinfo@ Media Contact:Amy KochDirector, Corporate Communicationsmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Illumina to Acquire SomaLogic for $350 Million, Expanding into Proteomics and Precision Medicine
Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc. (NASDAQ:ILMN) announced recently that it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) to acquire SomaLogic, a recognized leader in proteomics technology, for $350 million in cash at closing, along with up to $75 million in performance-based milestones and royalties. The deal includes the acquisition of SomaLogic's proprietary proteomics platform and other specified assets, further strengthening Illumina's position in multi-omic analysis and precision medicine. A research facility with medical professionals surrounded by diagnostic equipment. SomaLogic's platform enables high-throughput protein measurement and analysis, a critical advancement in understanding human biology at scale. By integrating these capabilities, Illumina aims to expand its clinical and research offerings into the proteomics space, complementing its core strength in genomics. This combination will provide researchers and clinicians with deeper biological insights, facilitating more informed decisions in drug development, diagnostics, and disease monitoring. The transaction is expected to close later this year, pending regulatory approvals and customary closing conditions. As a long-time pioneer in genetic sequencing, Illumina, Inc. (NASDAQ:ILMN) continues to evolve into a broader healthcare technology company. The company has increasingly embraced artificial intelligence and machine learning to analyze complex biological data. These capabilities allow for more accurate predictions in clinical outcomes and therapeutic response, positioning Illumina as an emerging leader in healthcare AI. This acquisition marks a strategic step forward, giving Illumina the tools to integrate genomic and proteomic data at scale, an essential move toward enabling truly personalized medicine. While we acknowledge the potential of ILMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
